MediCom Oncology Clinical Pearls Podcasts
We retired this podcast, because we couldn't parse it for 10 consecutive times.
- Website
- http://www.practicaloncologist.com/content/medonc_landing_page/
- Description
- MediCom Oncology Clinical Pearl Podcasts provide practical, evidence-based recommendations on real-world issues in the clinical setting, in under three minutes. Leading experts and academic faculty from top research and practice institutions provide guidance to community-based healthcare providers, including oncologists, pharmacists and nurses. Podcasts are brought to you by MediCom Worldwide, Inc., an accredited, independent medical education company. Podcasts are intended for licensed adult healthcare professionals (HCPs). HCPs should exercise professional judgment in evaluating content, and confirm information before implementing treatment or practice-related changes. Podcasts do not provide medical advice to patients.
- Language
- 🇬🇧 English
- last modified
- 2021-06-28 06:44
- last episode published
- 2018-10-26 16:17
- publication frequency
- 12.04 days
- Contributors
- Dockercast
- Owner
- MediCom Oncology
- Author
- Explicit
- false
- Number of Episodes
- 53
- Rss-Feeds
- Detail page
- Categories
- Science & Medicine
Recommendations
Episodes
| Date | Title & Description | Contributors |
|---|---|---|
| 2018-10-26 | Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML. |
|
| 2018-10-05 | Dr. Sallman describes a patient case demonstrating promise in the further study and potential use of CAR T-cell therapy for patients with AML. |
|
| 2018-10-05 |
Key considerations when prescribing midostaurin with a strong CYP3A4 inhibi Dr. Perl gives guidance on providing optimal patient therapy when prescribing midostaurin with a strong CYP3A4 inhibitor. |
|
| 2018-03-20 |
How to proceed with a patient who presents with idiopathic cytopenia of undetermined significance In this audio activity, Dr. Goldberg describes his approach to patients with idiopathic or clonal cytopenias of undetermined significance (ICUS and CCUS). |
|
| 2018-03-20 |
When to consider iron chelation therapy for a transplant-eligible patient Listen as Dr. Goldberg explains his approach to iron chelation therapy in patients who are, or may be within the next 5-10 years, eligible for transplant. |
|
| 2018-03-20 |
53-year-old woman presenting with severe fatigue and bruising Hematopathologist Dr. Khoury presents a case snapshot showing the complexities of diagnosing AML, describing the importance of morphology, flow cytometry, cytogenetics, and molecular diagnostics. |
|
| 2018-01-05 |
New subcategories of pancreatic cancer allow for a biomarker-driven approach to therapy Dr. O'Reilly discusses the new subcategories of pancreatic cancer that have emerged, and which are laying the groundwork for a biomarker-driven approach to therapy. |
|
| 2018-01-05 |
What are the unique aspects of pancreas cancer that lead to the development of novel therapeutics? Dr. O'Reilly discusses the unique pathophysiology of pancreas cancer that must be considered in the development of novel therapeutics. |
|
| 2018-01-05 |
Predictors of response to lenalidomide in a non-del(5q) MDS patient Listen as Dr. Goldberg discusses, in just under two minutes, the predictors of response to lenalidomide in a non-del(5q) MDS patient. |
|
| 2017-12-21 | Listen as Dr. Matasar discusses the pros and cons of radiation therapy, and who should be offered this therapy. |
|